Skip to main content
. 2023 Feb 9;141(3):275–283. doi: 10.1001/jamaophthalmol.2022.6254

Figure 1. Responder Analysis of Dosed Eyes in the Clinical Trial of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Using BIIB112 (XIRIUS) and Natural History of the Progression of X-Linked Retinitis Pigmentosa (XOLARIS) Studies.

Figure 1.

Responder analysis (achievement of ≥7-dB improvement from baseline at ≥5 of 16 central loci) in the XIRIUS trial part 1 therapeutic dose cohorts 3 to 6 using the dosed eyes compared with untreated eyes in the XIRIUS trial (A) and study eyes from participants in the XOLARIS study (B). The shading in panels A and B indicates the difference between the dosed and untreated eye in the XIRIUS trial (A) and the dosed eye in the XIRIUS trial and the study eye in the XOLARIS study (B). Mean retinal sensitivity in 16 central loci vs low-luminance visual acuity (VA) change from baseline for all visits up to month 12 in dosed (C) and untreated (D) fellow eyes among participants in XIRIUS part 1 cohorts 3 to 6 (n = 11; 1 participant had no baseline low-luminance VA). The correlation between change from baseline in mean retinal sensitivity in the 16 central loci assessed by macular integrity assessment microperimetry and low-luminance VA is shown. ETDRS indicates Early Treatment Diabetic Retinopathy Study.